alexa Are we Under Utilizing the Medical Therapies in Preventing the Complications in Peripheral Arterial Disease? | OMICS International
ISSN: 2329-6607
Cardiovascular Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Are we Under Utilizing the Medical Therapies in Preventing the Complications in Peripheral Arterial Disease?

Ramakrishna PK*

Department of Vascular Surgery, Nizam's Institute of Medical sciences, Panjagutta, Hyderabad, Telangana, India

*Corresponding Author:
Ramakrishna PK
Department of Vascular Surgery
Nizam's Institute of Medical sciences
Panjagutta, Hyderabad, 500082, Telangana
Tel: +91 23317115, +91 9848050243
E-mail: [email protected]

Received Date: April 13, 2017; Accepted Date: May 08, 2017; Published Date: May 15, 2017

Citation: Ramakrishna PK (2017) Are we Under Utilizing the Medical Therapies in Preventing the Complications in Peripheral Arterial Disease? Cardiovasc Pharm Open Access 6:211. doi: 10.4172/2329-6607.1000211

Copyright: © 2017 Ramakrishna PK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Cardiovascular Pharmacology: Open Access

Lower limb Peripheral Artery Disease (PAD) is the third most common cause of atherosclerotic cardiovascular morbidity after ischemic heart disease and stroke. Lower limb arterial disease is known to affect the quality of life of elderly people and it is associated increased cardiovascular complications and mortality. Smoking, Diabetes, Hypertension and hyper-lipidemic are the risk factors for peripheral vascular disease and the associated complications. The first global analysis of the lower limb arterial disease found that more than a quarter of a billion people in the world have the disease and poorer countries are disproportionately affected. Like many other life style diseases PAD incidence is also increasing during the past few decades. According to Fowkes G from the centre for population health sciences at the University of Edinburgh in Scotland, the global prevalence of PAD increased by 24% between 2000-2010, that is from 164 million to 202 million [1]. In this 21st century, peripheral artery disease has already become a global problem and we are looking for better solutions and preventive measures. Governments, non-governmental organizations, and the private sector in Low and middle income countries are evaluating the social and economic consequences, and assessing the best strategies for implementation of optimum treatments and preventive measures. Interventional therapies for peripheral arterial disease patients with different types of stents and balloons seem to be attractive but difficult to reach the large population. Adequate medical therapies such as cessation of smoking, diabetes care, antihypertensive medications, Statin therapies, antiplatelet therapies, anticoagulants and supervised exercise therapies can reach the people even in the remote places and helpful in preventing the worsening of the PAD and reduce the cardiovascular complications, amputations and mortality.

In the Edinburgh artery study of the general population found that the prevalence of peripheral arterial disease was high in the asymptomatic or symptomatic form. The prevalence of intermittent claudication was 4.5%. Major asymptomatic disease causing a significant impairment of blood flow occurred in 8.0%. A further 16.6% had criteria considered abnormal in clinical practice: 9.0% had ABPI less than 0.9 and 7.6% had reactive hyperaemia pressure reduction greater than 20%. Intermittent claudication was equally common in both sexes. Subjects with major asymptomatic lower limb arterial disease had more evidence of heart disease than in the normal population [2]. In PAD patients undergoing vascular surgery the longterm prognosis is significantly worse than that for the patients with Coronary Artery Disease (CAD). The patients who underwent vascular surgery received less cardiac medication and risk factor management than CAD patients. The cerebro-cardiovascular events are the major cause of late death in these patients after the vascular surgery in the long term [3].

Atherosclerosis affects numerous vascular beds to varying degrees. So, it is considered to be systemic disease. In patients with lower limb arterial disease, the prevalence of CAD was 46% to 71% [4,5]. The prognosis after vascular surgery in these patients is predominantly influenced by the underlying CAD in the early post-operative period and long term [6]. The cardiac death accounts for 40% in the first 30- day post-operative mortality and 6% to 10% in the 1-year mortality of vascular surgery patients [7].

We can improve the results in patients with PAD requiring surgery, with better evaluation of the risk factors and aggressive therapy of atherosclerotic risk factors. The secondary prevention measures in PAD patients are similar to the measures applied for patients with CAD. Aspirin is the antiplatelet drug and a better choice because of its low cost and the high incidence of CAD in PAD patients. It is interesting note that in the Physician Health Study of aspirin 325 mg every other day decreased the incidence of peripheral artery surgery [8].

Clopidogrel is used in patients who are allergic or intolerant to aspirin. In the CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) clopidogrel (75 mg/day) showed significant advantage over aspirin (325 mg/day) in preventing stroke, myocardial infarction and PAD in 19,185 patients after a recent stroke, myocardial infarction or PAD (The annual event rate was 5.3% vs. 5.8%) [9-12]. Cilostazol which is a phosphodiesterase inhibitor was approved by the FDA for the treatment of Intermittent Claudication. It is vasodilator and suppresses platelet aggregation. In a meta-analysis of 8 placebo-controlled randomized trials 2,702 patients with stable moderate to severe claudication were included. They were treated with cilostazol 100 mg twice daily for 12-24 weeks. It increased the maximal walking distance and pain-free walking distance by 50% and 67%. These effects were seen as early as a 1 month. The evidence of benefit supported the therapeutic trial for 3-6 months of cilostazol 100 mg twice daily to improve symptoms and increase walking distance in patients with lifestyle-limiting claudication. These are patients where antiplatelet agents and exercise rehabilitation are not helpful and revascularization cannot be done or refused by the patients. Prasugrel was introduced with lot of enthusiasm among patients with unstable angina or myocardial infarction without ST-segment elevation. But, prasugrel did not significantly reduce the frequency of the primary end point, when compared to the clopidogrel. The risks of bleeding were similar with Prasugrel and clopidogrel. The new antiplatelet drugs ticagrelol and prasugrel were promising options for treatment of PAD. Ticagrelor, is an inhibitor of platelet P2Y12 receptor, it has shown benefit acute coronary syndromes patients and stable coronary artery disease patients. Ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events in lower limb arterial disease patients. Major bleeding similarly among the patients receiving clopidogrel and ticagrelor.

Use of Statins in vascular surgery patients decreased the progression and even regressed growth of the atherosclerotic plaques. In patients with atherosclerosis of the lower limbs who have frequently concurrent coronary or cerebrovascular disease, use of statins resulted in decreased incidence of heart attacks and stroke. Statins are associated with pleiotropic benefits, such as anti-inflammatory effects which contribute to the additional beneficial effects and reduction in cardiovascular death. Many trials during the last few years showed that the statins improved pain-free walking distance, ankle brachial index and treadmill exercise time. So, the current guidelines for cholesterol reduction in PAD patients adhere to the same indications as for other cardiovascular diseases and strongly recommend the use of statins in these lower limb arterial disease patients [13].

Now, it is well understood that medical therapies are as important as the interventions in the vascular diseases. Earlier studies have documented under treatment of atherosclerotic risk factors among coronary artery disease patients. We realize that the atherosclerotic risk factor therapy and management may be even lower in PAD patients. If the strong association between PAD and cardiovascular mortality is not appreciated, it may also result in under treatment. Atherosclerotic risk factors are more aggressively treated among CAD patients than among PAD patients. PAD patients do not take the risk factor management advices sincerely. PAD patients fail to recall a physician’s advice to do exercise, do not recall dietary advice for hypercholesterolemia, and more likely to fail taking aspirin or warfarin [14]. If there are deficiencies in the physician knowledge and attitudes that can also contribute to lower rates of atherosclerotic risk factor reduction for PAD patients. If can improve these deficiencies one can certainly reduce the excess cardiovascular morbidity and mortality associated with PAD [15]. In the PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) program, PAD was identified in 29% of the participants out of 6,979 older patients in 350 general medicine practices across the United States. It is important note that compared to the participants with CVD diseases other than PAD, PAD participants in PARTNERS were under treated for hypertension and hyperlipidemia and received antiplatelet therapy less often. In adequate treatment can lead to high incidence of CVD morbidity and mortality in PAD patients [16]. Criqui et al. found that after the exclusion of participant with history of cardiovascular disease at base line, the relative cardiovascular risks among those with large-vessel peripheral arterial disease remained significantly elevated. The secondary analyses by them showed a 15-fold increase in rates of mortality due to cardiovascular disease and coronary heart disease among participants with large-vessel peripheral arterial disease which is severe and symptomatic [17].

Peripheral arterial disease in the lower limb is common in elderly people, these are at high risk of limb loss and higher mortality due to cardiovascular complications. There is urgent need for adequate medical therapies to prevent the complications and reduce the mortality. Adequate management of diabetes, hypertension, hyperlipidemia, appropriate use of antiplatelet drugs, anticoagulants, hemorheological agents along with cessation of smoking will be essential to prevent the morbidity and mortality vascular surgical patients [18].


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 25th Annual Congress on Cardiology and Medical Interventions
    July 16-17, 2018 Atlanta, USA
  • 6th Global Experts Meeting on Cardiology and Cardiovascular Pharmacology
    September 24-25, 2018 Tokyo, Japan
  • Current and Future trends in Cardio Vascular Diseases: Research and Outcomes
    October 05-06, 2018 Los Angeles, USA

Article Usage

  • Total views: 977
  • [From(publication date):
    June-2017 - Jul 16, 2018]
  • Breakdown by view type
  • HTML page views : 927
  • PDF downloads : 50

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7